Ticker: PLX

Protalix BioTherapeutics (NYSE American: PLX) sees stock tumble after EMA's CHMP rejects alternative dosing regimen for Elfabrio in Fabry disease treatment.

Protalix BioTherapeutics, Inc. (NYSE: PLX) Quick facts - latest quarter / six months (from Form 10‑Q ended June 30, 2025) * Total revenue (six months): $25,771 * Revenues from selling goods (six months): $25,435 * Cost of goods sold (six months): $(14,050) - gross profit = $11,721 * R&D (six mont...

Protalix BioTherapeutics, Inc. (NYSE: PLX) - Q1 2025 Financial Overview Protalix BioTherapeutics has published its financial results for the quarter ending March 31, 2025. The company, known for its biopharmaceutical focus on recombinant therapeutic proteins, is showing both promising growth in r...